Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
821
datasets available to search
ShareScore release 0.9.0
Dataset results
821 results for “anticoagulant”
EXCOR® Pediatric VAD Anticoagulation IDE
ClinicalTrials.gov study NCT03702192. IPD Sharing: NO. Countries: 0. Publications: 0.
Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy
ClinicalTrials.gov study NCT01810237. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
ClinicalTrials.gov study NCT02754154. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)
ClinicalTrials.gov study NCT02906527. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
ClinicalTrials.gov study NCT00005684. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Self-management of Anticoagulation Treatment
ClinicalTrials.gov study NCT02864537. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Enhanced Pharmacist-Managed Anticoagulation Service in a University-based Family Medicine Clinic
ClinicalTrials.gov study NCT03575936. IPD Sharing: NO. Countries: 0. Publications: 0.
EUS-FNA for Patients Taking Anticoagulants Without Heparin Bridge
ClinicalTrials.gov study NCT02977650. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Self-management of Anticoagulation Treatment
ClinicalTrials.gov study NCT02371772. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation
ClinicalTrials.gov study NCT03002740. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population
ClinicalTrials.gov study NCT07388056. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Point-of-Care Testing (POCT) for Guided Precision Anticoagulation With Warfarin: A Multicenter, Non-concurrent Controlled Study
ClinicalTrials.gov study NCT06645275. IPD Sharing: NO. Countries: 0. Publications: 0.
TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study
ClinicalTrials.gov study NCT06452342. IPD Sharing: NO. Countries: 0. Publications: 0.
Impact of different anticoagulants in obtaining reference profiles of exRNAs in healthy individuals (3)
GEO Series GSE235519. Homo sapiens. 80 samples. Type: Non-coding RNA profiling by array.
Choice of Valve Substitute in the Era of Oral Anticoagulation Self-Management
ClinicalTrials.gov study NCT01269905. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Data set from the article Prinzivalli M, Sammarco G, Rampoldi B, Costa E, Corsi Romanelli MM. Comparison between specific and nonspecific assay in the evaluation of the anticoagulant effect of the Direct Oral Anticoagulants: Our experience in a cardiovascular hospital. Eur J Intern Med. 2019;60:e20‐e22. doi:10.1016/j.ejim.2018.10.005
<p>Data set from the article Prinzivalli M, Sammarco G, Rampoldi B, Costa E, Corsi Romanelli MM. Comparison between specific and nonspecific assay in the evaluation of the anticoagulant effect of the Direct Oral Anticoagulants: Our experience in a cardiovascular hospital. <em>Eur J Intern Med</em>. 2019;60:e20‐e22. doi:10.1016/j.ejim.2018.10.005</p>
Nursing self-efficacy for oral anticoagulant therapy management: Development and initial validation of a theory-grounded scale
<p>Dataset from Magon A, Arrigoni C, Fava A, Pittella F, Villa G, Dellafiore F, Conte G, Caruso R. Nursing self-efficacy for oral anticoagulant therapy management: Development and initial validation of a theory-grounded scale. Appl Nurs Res. 2021 Jun;59:151428. doi: 10.1016/j.apnr.2021.151428. Epub 2021 Mar 23. PMID: 33947515.</p> <p>Abstract</p> <p><strong>Aim: </strong>This study aimed to develop and validate a nursing self-efficacy scale for OAC management (SE-OAM).</p> <p><strong>Background: </strong>Oral anticoagulant therapy (OAC) requires specific nursing competencies. Given that self-efficacy acts as a proxy assessment of nursing competence, its measurement is pivotal for addressing educational programs to enhance nursing competence in managing OAC. Thus far, the measurement of self-efficacy in OAC is undermined by the unavailability of valid and reliable tools.</p> <p><strong>Methods: </strong>A multi-method and multi-phase design was adopted: Phase one was a methodological study encompassing developmental tasks for generating items. Phase two comprised the validation process for determining the content validity, construct and concurrent validity, and internal consistency through two cross-sectional data collections.</p> <p><strong>Results: </strong>In total, 190 nurses were enrolled for determining the psychometric structure of the SE-OAM through an exploratory approach, and 345 nurses were subsequently enrolled to corroborate its most plausible factor structure derived from the exploratory analysis. The SE-OAM showed evidence of face and content validity, adequate construct, concurrent validity, good internal consistency, and stability. The final version of the scale encompassed 21 items kept by five domains: clinical management, care management, education, clinical monitoring, and care monitoring.</p> <p><strong>Conclusions: </strong>The SE-OAM showed evidence of initial validity and reliability, fulfilling a current gap in the availability of tools for measuring nursing self-efficacy in managing OAC. SE-OAM could be strategic for performing research to improve the quality of OAC management by enhancing nursing self-efficacy.</p>
Managing anticoagulation in the COVID-19 era between lockdown and reopening phases: Comment.
<p>Dataset from Magon A, Arrigoni C, Barello S, Graffigna G, Caruso R. Managing anticoagulation in the COVID-19 era between lockdown and reopening phases: Comment. Intern Emerg Med. 2021 Oct;16(7):2017-2018. doi: 10.1007/s11739-021-02647-6. Epub 2021 Feb 10. PMID: 33566279; PMCID: PMC7873665.</p>
The effect of health literacy on vaccine hesitancy among Italian anticoagulated population during COVID-19 pandemic: the moderating role of health engagement
<p>Magon A, Arrigoni C, Graffigna G, Barello S, Moia M, Palareti G, Caruso R. The effect of health literacy on vaccine hesitancy among Italian anticoagulated population during COVID-19 pandemic: the moderating role of health engagement. Hum Vaccin Immunother. 2021 Oct 13:1-6. doi: 10.1080/21645515.2021.1984123. Epub ahead of print. PMID: 34643478.</p> <p>Abstract</p> <p>Assessing vaccine hesitancy and its determinants is pivotal to optimize vaccine acceptance in anticoagulated patients, given that this population has been described to have a higher risk of severe COVID-19-related complications. This study assessed the moderator role of patients' health engagement on the relationship between health literacy and vaccine hesitancy. A web-based survey was performed in Italy during the first wave (June-August 2020) and the second wave (October 2020-March 2021) of the COVID-19 pandemic, enrolling 288 patients. The rates of vaccine hesitancy reported during the first pandemic wave were 38.4% and 30.8% during the second wave (when a vaccine was available) (<em>p</em> = .164). A moderation analysis was performed to assess the role of health engagement in influencing the relationship from health literacy to vaccine hesitancy. Patients' health engagement enhanced the effects of health literacy on decreasing vaccine hesitancy (<em>p</em> < .001), suggesting that co-construction strategies for communicative action are pivotal.</p>
Dataset related to the article "Leadless pacemaker implant, anticoagulation status, and outcomes: Results from the Micra Transcatheter Pacing System Post-Approval Registry"
<p>This record contains raw data related to the article "Leadless pacemaker implant, anticoagulation status, and outcomes: Results from the Micra Transcatheter Pacing System Post-Approval Registry". </p> <p> </p> <p><strong>Abstract</strong></p> <p><strong>Background: </strong>Early results from the Micra investigational trial and Micra Post-Approval Registry (PAR) demonstrated excellent safety and device performance; however, outcomes based on anticoagulation (AC) status at implant have not been evaluated.</p> <p><strong>Objective: </strong>The purpose of this study was to report implant characteristics, perforation rate, and vascular-related events based on perioperative oral AC strategy in patients undergoing Micra implant.</p> <p><strong>Methods: </strong>We compared procedure characteristics, major complications, and vascular events, including pericardial effusion, stratified by any adverse event (including major complications, minor complications, and observations) or major complication only according to AC status in the Micra PAR.</p> <p><strong>Results: </strong>Among 1795 patients with AC status available, 585 were not on AC, 795 had AC interrupted, and 415 had AC continued during Micra implant. Non-AC patients tended to be younger, with less history of atrial fibrillation and chronic obstructive pulmonary disease, and more history of dialysis than interrupted and continued patients. The implant success rate was similar for all groups (99.1%-99.8%). Through 30 days postimplant, the overall major complication rate was 3.1% for the non-AC group, 2.6% for the interrupted group, and 1.5% for the continued group. The combined rate for any vascular or pericardial effusion adverse event did not differ significantly among AC strategies (6.5%, 4.8%, and 3.6%, respectively).</p> <p><strong>Conclusion: </strong>Implant of Micra seems to be safe and feasible regardless of an interrupted or continued periprocedural oral AC strategy, with no increased risk of perforation or vascular complications.</p> <p><strong>Trial registration: </strong>ClinicalTrials.gov <a href="http://clinicaltrials.gov/show/NCT02536118">NCT02536118</a>.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.